Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Date:6/23/2011

AMSTERDAM, June 24, 2011 /PRNewswire/ --


 

- Dossier Re-Examination Process Initiated

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera® (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD"). Following a recent meeting with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), AMT has been notified that, at this time, Glybera is not approvable.

Subsequent to a review of the CHMP's letter, AMT believes that Glybera can receive a positive opinion subject to generating additional data from existing patients. AMT has therefore decided to ask for a re-examination of the clinical data package.

"From what we know today, despite the disappointment, we believe that there is an indication from the CHMP that Glybera could receive approval and that the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for chylomicron handling for at least 12 months post treatment. The CHMP also indicated that if certain additional data from already treated patients would confirm current results by the end of 2011, an approval may be possible," noted Jörn Aldag, CEO of AMT. "In the dossier, we provided important data showing Glybera is safe and prevents episodes of pancreatitis, the major clinical complication of LPLD. We appreciate the CHMP's responsibility for caution on such an advanced therapy, so we will work diligently to generate more information and, we hope, ensure that Glybera will still reach patients."

Next steps

As part of the MAA, AMT presented data to the CHMP on Glybera showing evidence in reducing the risk of pancreatitis. Also, the company demonstrated a clear signal of patients' ability to b
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011
2. Amsterdam Molecular Therapeutics Reports Promising Data From Cholesterol Lowering Gene Therapy Study
3. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
4. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
5. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
6. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
7. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
8. The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
9. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
10. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
11. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
(Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
(Date:10/30/2014)... 2014 The global newborn screening market ... technology, product, and geography. The mass spectrometry market ... in the newborn screening market by technology, during ... to various nations opting for expanded newborn screening. ... for expanded newborn screening. Furthermore, various conferences and ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... 11 El Camino Hospital, the hospital of Silicon ... da Vinci® Si HD Surgical Systems. Physicians performed more ... expect the number to increase in 2010 as more ... for more minimally invasive procedures. The new systems feature ...
... BROOMFIELD, Colo., Nov. 11 Accera, Inc., a biotechnology company ... that it will present at Lazard Capital Markets 6th Annual ... in New York. , Steve Orndorff, Ph.D., founder, president ... an update on Axona (TM) on Tuesday, November 17 ...
Cached Medicine Technology:El Camino Hospital Expands Robotic Surgery Program 2El Camino Hospital Expands Robotic Surgery Program 3El Camino Hospital Expands Robotic Surgery Program 4Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference 2
(Date:10/30/2014)... 2014 USARAD Holdings Inc ... and specialty telemedicine solutions provider, including SecondOpinions.com ... existing teleradiology services at Mission Bend ER, it ... telemedicine services, to the state-of-the-art, 24/7, freestanding ER ... of this innovative partnership, there will be many ...
(Date:10/30/2014)... WA (PRWEB) October 30, 2014 Sound Telecom, ... decision infographic that will assist people any time they wonder, ... discover the right answer by leading them through a series ... resolution to their initial query. , There are many considerations ... not to use an answering service . This decision ...
(Date:10/30/2014)... News) -- Many U.S. colleges have indoor tanning ... increases the risk for skin cancer, researchers report. ... white women, so colleges should adopt tanning-free policies, ... "Public health efforts are needed to raise ... harms that indoor tanning poses to young adults ...
(Date:10/30/2014)... 29, 2014) – A new standard of care for ... following a multi-year study published in the latest edition ... , The research, led by John Wagner, Jr., M.D., ... at the University of Minnesota and a researcher in ... in children with acute leukemia and myelodysplastic syndrome who ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:New insights into the development of ciliopathies 2
... the seventh leading cause of cancer death worldwide, the ... group and gender. Esophageal cancer is thought to be ... with the host genome. Researchers have long been seeking ... conducted on gene-environment interaction and gene polymorphisms for esophageal ...
... intellectual property laws devalue the "repurposing" of existing ... life-saving treatments, a Portland researcher contends. , S. ... behavioral neuroscience in the Oregon Health & Science ... Affairs Medical Center, writes in a letter appearing ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... severe Alzheimer,s disease for the quarter ended June ... royalty payments compared to,the same quarter last year, ...
... Oct. 31 MAP,Pharmaceuticals, Inc. (Nasdaq: ... the initiation of a Phase 2a clinical ... asthma and chronic obstructive,pulmonary disease (COPD). ... and a long-acting,beta2-agonist delivered to the respiratory ...
... and Offshore Healthcare Expertise and ... Service Delivery Capabilities EL SEGUNDO, Calif. ... CSC ) and,First Consulting Group, Inc. (Nasdaq: FCGI ) today ... through which CSC will acquire,First Consulting Group (FCG) in an all-cash ...
... EDMONTON, Oct. 31 /PRNewswire-FirstCall/ - BioMS Medical Corp ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... Rodman and Renshaw 9th Annual Healthcare Conference in ... 3:20 pm (Local Time), WHERE: New York ...
Cached Medicine News:Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Old drugs need 'repurposing' for new uses, physician says 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:CSC Agrees to Acquire First Consulting Group 2Health News:CSC Agrees to Acquire First Consulting Group 3Health News:CSC Agrees to Acquire First Consulting Group 4Health News:CSC Agrees to Acquire First Consulting Group 5Health News:BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: